As of 2025-12-23, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -6.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 843.35 mil USD. NKTR's TTM EBITDA according to its financial statements is -134.93 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 15.4x | 11.7x |
| Forward P/E multiples | 13.2x - 15.5x | 14.6x |
| Fair Price | (85.28) - (100.14) | (85.38) |
| Upside | -296.1% - -330.3% | -296.4% |
| Date | EV/EBITDA |
| 2025-12-19 | -6.76 |
| 2025-12-18 | -6.33 |
| 2025-12-17 | -6.54 |
| 2025-12-16 | -7.11 |
| 2025-12-15 | -7.73 |
| 2025-12-12 | -7.94 |
| 2025-12-11 | -7.40 |
| 2025-12-10 | -8.40 |
| 2025-12-09 | -8.56 |
| 2025-12-08 | -8.33 |
| 2025-12-05 | -8.27 |
| 2025-12-04 | -8.39 |
| 2025-12-03 | -8.31 |
| 2025-12-02 | -7.96 |
| 2025-12-01 | -8.91 |
| 2025-11-28 | -9.53 |
| 2025-11-26 | -9.60 |
| 2025-11-25 | -8.79 |
| 2025-11-24 | -8.54 |
| 2025-11-21 | -7.88 |
| 2025-11-20 | -8.00 |
| 2025-11-19 | -8.79 |
| 2025-11-18 | -8.62 |
| 2025-11-17 | -8.68 |
| 2025-11-14 | -8.24 |
| 2025-11-13 | -7.83 |
| 2025-11-12 | -8.39 |
| 2025-11-11 | -8.63 |
| 2025-11-10 | -8.43 |
| 2025-11-07 | -8.13 |
| 2025-11-06 | -8.01 |
| 2025-11-05 | -7.88 |
| 2025-11-04 | -8.14 |
| 2025-11-03 | -8.73 |
| 2025-10-31 | -9.48 |
| 2025-10-30 | -9.16 |
| 2025-10-29 | -8.69 |
| 2025-10-28 | -8.88 |
| 2025-10-27 | -9.13 |
| 2025-10-24 | -8.76 |
| 2025-10-23 | -9.29 |
| 2025-10-22 | -9.01 |
| 2025-10-21 | -8.65 |
| 2025-10-20 | -9.19 |
| 2025-10-17 | -8.40 |
| 2025-10-16 | -7.98 |
| 2025-10-15 | -8.27 |
| 2025-10-14 | -8.30 |
| 2025-10-13 | -8.35 |
| 2025-10-10 | -7.89 |